Every 8-K that Aurinia Pharmaceuticals Inc (AUPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AUPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AUPH filings page.
Aurinia Pharmaceuticals Inc. (AUPH) reports that it and its U.S. subsidiary have entered into a settlement agreement with Teva Pharmaceuticals Inc. resolving U.S. patent litigation over Teva’s proposed generic 7.9 mg voclosporin oral capsules. Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991, which expire in December 2037, are enforceable, valid, and would be infringed by commercial sales of its generic product in the United States.
The settlement permits Teva to launch its generic voclosporin product in the United States no earlier than December 7, 2036, subject to defined contingencies and to obtaining FDA approval. Aurinia’s related patent infringement actions continue against several other generic manufacturers in the U.S. District Court for the District of New Jersey.
Aurinia Pharmaceuticals Inc. reported strong financial results for the three and six months ended June 30, 2026. Total revenue reached $83.2 million for the quarter and $160.9 million year-to-date, up 19% and 21% from 2025, driven mainly by LUPKYNIS net product sales of $79.4 million and $153.0 million. Net income was $37.4 million for the quarter and $71.8 million for the first half, while diluted EPS rose to $0.28 and $0.53.
Cash flows from operating activities were $52.5 million in Q2 and $85.1 million for the first half, supporting cash, cash equivalents, restricted cash and investments of $443.1 million as of June 30, 2026. Aurinia repurchased 5.0 million common shares for $74.9 million. The company reiterated 2026 guidance for total revenue of $315 million to $325 million and LUPKYNIS net product sales of $305 million to $315 million. It also initiated PRESERVE, a Phase 4 study combining LUPKYNIS with biologic agents in lupus nephritis, and advanced aritinercept into clinical development in four potential autoimmune indications.
Aurinia Pharmaceuticals Inc. reported the results of its 2026 annual general meeting, held virtually. Shareholders elected Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson and Tina S. Nova to the board of directors, with support for each nominee ranging from 86.50% to 96.59% of votes cast.
Shareholders also approved the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm, with 89.14% of votes cast in favor. In addition, they approved, on a non-binding advisory basis, the company’s executive compensation in a “say on pay” vote, with 93.10% of votes cast supporting the resolution.
Aurinia Pharmaceuticals Inc. completed its acquisition of Kezar Life Sciences through a tender offer and follow-on merger. Kezar stockholders received $6.955 in cash per share plus one contingent value right, with 5,927,580 shares tendered, representing about 80.24% of outstanding shares at expiration.
After the tender offer closed, Aurinia merged its subsidiary into Kezar under Delaware law, making Kezar a wholly owned subsidiary. In-the-money Kezar stock options became fully vested and were cashed out for the cash portion of the offer plus CVRs, while out-of-the-money options were cancelled with no payment. Kezar’s employee stock purchase plan was terminated immediately before the merger became effective.
Aurinia Pharmaceuticals reported strong results for the three months ended March 31, 2026. Total revenue reached $77.7 million, up 24% from $62.5 million a year earlier, driven mainly by LUPKYNIS net product sales of $73.6 million, up 23%.
Net income was $34.4 million, a 48% increase from $23.3 million, with diluted earnings per share rising to $0.25 from $0.16. Operating cash flow improved sharply to $32.6 million from $1.3 million, while cash, cash equivalents, restricted cash and investments totaled $378.8 million as of March 31, 2026.
The company repurchased 2.5 million common shares for $36.2 million during the quarter and reaffirmed 2026 guidance, targeting total revenue of $315–$325 million and LUPKYNIS net product sales of $305–$315 million.
Aurinia Pharmaceuticals Inc. plans to acquire Kezar Life Sciences through a tender offer at $6.955 in cash per share plus one non-transferable contingent value right (CVR) for each Kezar share. After the offer, a follow-on merger will make Kezar a wholly owned Aurinia subsidiary under Delaware’s Section 251(h) process.
The CVR will give Kezar stockholders potential additional cash tied to Kezar’s closing net cash above $50.0 million, proceeds from existing Enodia and Everest agreements, and future monetization or development of zetomipzomib and other legacy assets over up to 10 years. A key Kezar holder owning about 9.0% of the stock has agreed to tender its shares, and closing is targeted for the second quarter of 2026, subject to minimum tender, net cash and other customary conditions.
Aurinia Pharmaceuticals Inc. announced a major management transition, appointing Kevin Tang, currently Chair of the Board, as Chief Executive Officer and principal executive officer effective March 23, 2026. Tang has a long background in life sciences investing and biotech leadership and has elected to receive no salary, bonuses, equity awards or other compensation from Aurinia.
The Board also appointed Ryan Cole as Chief Operating Officer and Michael Hearne as Chief Financial Officer, principal financial officer and principal accounting officer, each with a $300,000 annual base salary, a target bonus equal to 50% of base salary, and a new hire option to purchase 150,000 Aurinia common shares. On March 20, 2026, prior officers including CEO Peter Greenleaf, COO Matthew Donley, CMO Gregory Keenan and CFO Joseph Miller ceased serving as officers, and Greenleaf resigned from the Board on March 21, 2026 but will consult for three months at $600 per hour to support the transition.
The Board created a new Lead Independent Director role and elected current independent director Craig Johnson to that position to help coordinate independent director activities and serve as liaison with the Chair and senior management.
Aurinia Pharmaceuticals reported strong growth for 2025, driven by its lupus nephritis drug LUPKYNIS. Total revenue reached $283.1 million for the year, up 20% from 2024, with LUPKYNIS net product sales rising 25% to $271.3 million.
The company moved to solid profitability, with 2025 net income of $287.2 million versus $5.8 million a year earlier, helped by a large income tax benefit from releasing a valuation allowance on deferred tax assets. Cash, cash equivalents, restricted cash and investments were $398.0 million as of December 31, 2025, after repurchasing 12.2 million common shares for $98.2 million. For 2026, Aurinia guides to total revenue of $315–$325 million and LUPKYNIS net product sales of $305–$315 million, implying low- to mid-teens percentage growth.
Aurinia Pharmaceuticals Inc. (AUPH) furnished an 8‑K on November 4, 2025 announcing it issued a press release for its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, with a Third Quarter 2025 Update as Exhibit 99.2.
The information was furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The report was signed by Chief Financial Officer Joseph Miller.